雷帕霉素治疗肾移植术后肿瘤八例

Therapeutic effect of rapamycin in the treatment of malignancies in recipients after kidney transplantation

目的探讨雷帕霉素(RPM)在肾移植后发生肿瘤治疗中的作用。方法23例肾移植术后发生肿瘤而无法手术切除的患者,8例在调整免疫抑制方案的同时加用RPM(RPM组),15例调整免疫抑制方案,部分患者接受化疗(非RPM组),对比两组患者的存活情况。结果RPM组患者治疗期间未见急性排斥反应,其中位存活时间为14.5个月,随访至今,仍有7例存活;1例Kaposi肉瘤患者减少RPM用量而发生急性排斥反应,最终因移植肾功能衰竭和肺部感染死亡。非RPM组患者的中位存活时间为3.0个月,随访期内全部死亡。RPM组12个月、20个月的存活率分别为75.0%和37.5%,非RPM组12个月、20个月的存活率分别为7.1%和0,两组间的差异有统计学意义(P<0.05)。结论RPM发挥抗急性排斥反应作用的同时,对肿瘤的发生、发展也有抑制作用。

Objective To investigate the therapeutic effect of rapamycin in the treatment of malignancies after kidney transplantation (KT).Methods Of the 23 inoperable patients with malignancies after KT, 8 (RPM group) received Rapamycin as treatment as well as there immunosuppressive regimens were modulated, and the remaining 15 (non-RPM group) were treated only by immunosuppressive regimen modulation, some of whom also received chemotherapy. The survival of the patients in the two groups was compared.Results In RPM group, the median survival time was (14.5) months and no acute rejection (AR) occurred during whole follow-up period. There are still 7 patients alive at the end of this study. One recipient with Kaposi’s sarcoma developed AR because of RPM dose reduction, and finally died of transplanted kidney failure and pulmonary infection. In non-RPM group, the median survival time was (3.0) months, and all of them died during the follow-up period. The 12- and 20-month survival rates were respectively (75.0) % and (37.5) % in RPM group, while (7.1) % and 0 in non-RPM group with the difference being statistically significant (P<(0.05)).Conclusion As a new type of immunosuppressant, Rapamycin can not only prevent the generation of AR, but also inhibit generation and development of malignancy in KT recipients.